Cybele Holdings
VC Fund
Ramat Gan, Israel
Cybele Holdings is a VC fund in Ramat Gan focused on Health Care and Biotechnology. Cybele Group is a full service consulting and financial services firm, which provides investment banking, brokerage and asset management services to both corporations and a wide array of clients, ranging from individuals and small businesses to the world's largest corporations and governments.
- Total investments:
- 84
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Cybele Holdings invests in
Stages Cybele Holdings invests in
Countries Cybele Holdings invests in
Round sizes
Round size
- Post-IPO Equity
- $712k–$77M
- Venture - Series Unknown
- $771k–$86M
Investment Focus
Industry
- Health Care 14 (17%)
- Biotechnology 13 (15%)
- Real Estate 12 (14%)
- Medical 9 (11%)
- Manufacturing 8 (10%)
Stage
- Post-IPO Equity 30 (36%)
- Venture - Series Unknown 25 (30%)
- Series D 1 (1%)
- Post-IPO Debt 1 (1%)
- Private Equity 1 (1%)
Country
- Israel 46 (55%)
- United States 6 (7%)
- Cyprus 2 (2%)
- Norway 1 (1%)
- United Kingdom 1 (1%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Silverbyte is a leading supplier of property management software solutions. Silverbyte’s premium applications are designed to meet the growing needs of the hospitality industry even with the changes that the industry is going through.Due to the technological progress such as various online booking and review platforms, hotels have to distinctthemselves from their competitors. | $35.9M / Venture - Series Unknown / Jun 01, 2022 | ||
| Smart Agro specializes in investing and improving companies in the agro-tech fields. | $4.5M / Post-IPO Equity / Aug 01, 2021 | ||
| Cannabotech develop, and assimilate the medicinal properties of Cannabinoids & Mushrooms, integrated with cutting-edge technologies at world-class standards. | $8M / Venture - Series Unknown / Jul 01, 2021 | ||
| Protalix is a biopharmaceutical company that is revolutionizing the development and manufacturing of recombinant therapeutic proteins through its ProCellEx® plant cell-based protein expression system. Using ProCellEx, Protalix is focused on the development and commercialization of a proprietary pipeline of novel and biosimilar proteins that targetlarge, established pharmaceutical markets and that rely upon known biological mechanisms of action. Protalix’s initial commercial focus is on complex therapeutic proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. Protalix is also advancing additional recombinant biopharmaceutical drug development programs, including a TNF inhibitor for inflammatory diseases.Protalix’s pipeline is led by ELELYSO™(taliglucerase alfa for injection), which received approval from the U.S. Food and Drug Administration on May 1, 2012. ELELYSO is the first FDA-approved plant cell-based recombinant therapeutic protein. Protalix has partnered with Pfizer for worldwide development and commercialization of ELELYSO, excluding Israel, where Protalix has retained full rights. Marketing applications for taliglucerase alfa have been submitted for Europe, Israel, Brazil and Australia, with additional regulatory submissions in progress. | $40M / Post-IPO Equity / Feb 11, 2021 | ||
| Itamar Medical is a publicly traded medical device company based in Israel’s Caesarea Industrial Park that develops non-invasive medical devices using the proprietary PAT (Peripheral Arterial Tone) signal.Since its founding in 1997, the Company has engaged in research and development of non-invasive medical devices for diagnosis of variousmedical conditions, including cardiovascular disease and respiratory disorders.The first two product lines from Itamar Medical, based on unique technology developed by the Company, are the WatchPAT™ home appliance for respiratory sleep disorder diagnosis, and EndoPAT™, the only device approved by the FDA for testing endothelial (arterial) function and assessing the risk of coronary artery disease and other cardiovascular diseases. | $70M / Post-IPO Secondary / Feb 07, 2021 | ||
| Z.M.H Hammerman is a construction company. They engaged in the initiation and execution of large residential, office, and commercial projects, as well as the execution of other projects. | $24.3M / Post-IPO Equity / Feb 01, 2021 | ||
| HomeBioGas offers the most advanced, compact and cost-effective anaerobic digesters that convert kitchen waste and animal manure into cooking gas and liquid fertilizer, while maintaining highest safety and health standards. | $30.3M / Venture - Series Unknown / Feb 01, 2021 | ||
| Millennium Food-Tech is an R&D partnership traded on the Tel Aviv Stock Exchange that specializes in investment in and betterment of companies in food-tech sectors,. Millennium seeks to invest in companies that specialize in identifying and developing innovative, and transformative ideas in the food, drinks, and nutrition industry. Millenniumhas experienced management, proven solutions, and a supportive network to develop ideas and start-ups from early-stage to maturity to exit. | $16.1M / Private Equity / Dec 01, 2020 | ||
| Micronet (TASE:MCRNL) has been developing, manufacturing and marketing mobile computing platforms, designed for integration into fleet management and mobile workforce management solutions. Such solutions facilitate mobile workforce productivity, enable corporate efficiency, and enhance customer service.The company focuses on the MRM (MobileResource Management) vertical industries within the automotive market: Fleet management / MRM – featuring the industry's most extensive line of Mobile Data Terminals, fixed and portable, for a variety of fleet and workforce management applications. | $12.4M / Venture - Series Unknown / Oct 01, 2020 | ||
| Novocure™ is dedicated to the development of tumor treating fields therapy (NovoTTF™ Therapy), a new weapon for patients and physicians in the battle against cancer. NovoTTF Therapy is a novel anti-mitotic treatment that has been shown to slow or reverse tumor progression by inducing cell death in certain solid tumors. The company pioneered theconcept that the electric properties of cells can be used as an effective target for an anti-neoplastic therapy. | $15.5M / Post-IPO Debt / Sep 01, 2020 | ||
| See all 84 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Cybele Holdings invest in?
Cybele Holdings invests primarily in Health Care, Biotechnology and Real Estate startups, most often at Post-IPO Equity and Venture - Series Unknown stage. Most of the 84 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Cybele Holdings invest in?
Cybele Holdings typically joins rounds of $712k–$77M at Post-IPO Equity and $771k–$86M at Venture - Series Unknown. These are whole funding-round sizes, not Cybele Holdings's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Cybele Holdings took part in.
When did Cybele Holdings last invest?
The most recent investment recorded for Cybele Holdings closed in Jun 2022. Shizune tracks 84 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
